Skip to content

Residence Time Evaluation of Marketed OTC Ophthalmic Products

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00804791
Enrollment
25
Registered
2008-12-09
Start date
2008-11-30
Completion date
Unknown
Last updated
2012-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye

Keywords

dry eye, autofluorescence, residence time

Brief summary

The objective of this study is to measure ocular surface residence time (in minutes) of two marketed OTC ophthalmic products in dry eye patients.

Interventions

artificial tears solution for lubricating the cornea

saline solution for irrigating the cornea

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Informed consent and HIPAA read, signed and dated before conducting any procedures. * Adult volunteers diagnosed with mild to moderate dry eye. Criteria for diagnosis must include 2 of the 3 following characteristics: composite symptom score \> or = to 5 on modified Schein questionnaire; NaFl TFBUT \< or = to 7 seconds in either eye; or NaFl corneal staining sum score \> or = to 3 (using 0-15 point grading system). * Able and willing to follow study instructions. 4) Best-corrected V.A. of 0.6 logMAR or better OU.

Exclusion criteria

* History or evidence of ocular or intraocular surgery in either eye w/i the past 6 months. * History or evidence of serious ocular trauma in either eye w/i the past 6 months. * History of intolerance or hypersensitivity to any component of the study medications. * History or evidence of epithelial herpes simplex keratitis, vaccinia, active or recent varicella viral disease of the cornea and/or conjunctiva and/or eyelids, mycobacterial infection of the eye, and/or fungal disease of the eye. * Use of concomitant topical ocular medications during the study period. * Patients using systemic medications that may contribute to dry eye may not be enrolled unless they have been on a stable dosing regimen for a minimum of 30 days prior to Visit 1, and the dosing regimen must remain stable throughout the study period. * Ocular conditions such as conjunctival infections, iritis, or any other ocular condition that may preclude the safe admininstration of the test article. * Individuals unwilling to d/c contact lens wear during the study period. CL wear must have been d/c at least one week prior to Visit 1. * Participation in an investigational drug or device study w/i 30 days of entering this study. * Additionally, any subject may be declared ineligible for a valid medical reason.

Design outcomes

Primary

MeasureTime frameDescription
Ocular Surface Residence TimeAfter 8 minutes, then every 2 minutesOcular surface residence time is the time for fluorescent intensity of the cornea to return to baseline measurement after installation of test article.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026